IGN 201

Drug Profile

IGN 201

Alternative Names: IGN-201; MyVaccine®

Latest Information Update: 05 Nov 2009

Price : $50

At a glance

  • Originator igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 05 Nov 2009 Discontinued - Preclinical for Cancer in Austria (unspecified route)
  • 29 Mar 2005 igeneon Krebs Immuntherapie Forschungs und Entwicklungs AG has been acquired by Aphton Corporation
  • 07 Aug 2002 Preclinical trials in Cancer in Austria (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top